Clinical trials: Stage III Cervical Cancer
- Condition Stage III Cervical Cancer
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Cervical Cancer
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or…
- Trial name
- NCT00770874
- Testing
- S-1 + Cisplatin (arm A), Cisplatin (arm B)
- Where
- 4 sites in Japan, South Korea and 1 more
- Volunteers
- 375 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Thyroid Neoplasms
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine
- Trial name
- NCT00984282
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 81 sites in United States, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Bayer
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as…
- Trial name
- NCT03189719
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 749 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell…
- Trial name
- NCT05386550
- Testing
- Xevinapant, IMRT
- Where
- 206 sites in United States, Argentina and 24 more
- Volunteers
- 166 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Neoplasms
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and…
- Trial name
- NCT03040999
- Testing
- Pembrolizumab, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 804 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Gastrointestinal Tract
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
This was an international multi-center trial that enrolled patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors had amplification of the ErbB2 (HER2)…
- Trial name
- NCT00680901
- Testing
- Lapatinib, Capecitabine, Oxaliplatin
- Where
- 183 sites in United States, Argentina and 21 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Carcinoma of the Head and Neck
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of…
- Trial name
- KESTREL (NCT02551159)
- Testing
- MEDI4736, Tremelimumab, MEDI4736+Tremelimumab
- Where
- 197 sites in United States, Austria and 21 more
- Volunteers
- 823 people
- Sponsor
- AstraZeneca
Esophageal Carcinoma
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the…
- Trial name
- NCT03099382
- Testing
- camrelizumab, Docetaxel, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 457 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neoplasms, Head and Neck
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo.
- Trial name
- NCT00387127
- Testing
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Anaplastic Thyroid Cancer
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
- Trial name
- FACT (NCT00507429)
- Testing
- CA4P, paclitaxel, carboplatin
- Where
- 41 sites in United States, Belarus and 10 more
- Volunteers
- 80 people
- Sponsor
- Mateon Therapeutics
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed…
- Trial name
- NCT03933449
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Where
- 23 sites in China
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Oral Cavity
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
The purpose of this study is to determine whether a pre-operative regimen of the study drug, IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single dose of cyclophosphamide, followed by 21…
- Trial name
- INSPIRE (NCT02609386)
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Where
- 22 sites in United States, Brazil and 2 more
- Volunteers
- 105 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Locally Advanced Cervical Cancer
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With…
- Trial name
- CALLA (NCT03830866)
- Testing
- Durvalumab, Cisplatin, Carboplatin
- Where
- 117 sites in United States, Brazil and 13 more
- Volunteers
- 770 people
- Sponsor
- AstraZeneca
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head…
- Trial name
- CHANGE2 (NCT02383966)
- Testing
- Cetuximab, Cisplatin/Carboplatin, 5-fluorouracil
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00122681
- Testing
- Cervarix™, Havrix™-based investigational formulation
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 18,729 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
The purpose of this study is to evaluate the tolerability and safety of Xevinapant when added to weekly cisplatin-based concurrent chemoradiotherapy (CRT) in the treatment of participants with unresectable locally advanced…
- Trial name
- NCT06056310
- Testing
- Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT)
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 18 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.